Real-world study of trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer

Trial Identifier: D9673R00055
Sponsor: AstraZeneca
Start Date: January 2025
Primary Completion Date: October 2027
Study Completion Date: October 2027
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Bulgaria, Burgas Burgas, Bulgaria, 8000
Bulgaria, Pazardzhik Panagyurishte, Pazardzhik, Bulgaria, 4500
Bulgaria, Plovdiv Plovdiv, Bulgaria, 4004
Bulgaria, Sofia Sofia, Bulgaria, 1756
Bulgaria, Sofia Sofia, Bulgaria, 1330
Bulgaria, Sofia Sofia, Bulgaria, 1407
Bulgaria, Sofia Sofia, Bulgaria, 1431
Bulgaria, Sofia Sofia, Bulgaria, 1618
Bulgaria, Sofia Sofia, Bulgaria, 1527
Bulgaria, Sofia Sofia, Bulgaria, 1303
Bulgaria, Stara Zagora Stara Zagora, Bulgaria, 6003
Bulgaria, Varna Varna, Bulgaria, 9003
Slovenia Ljubljana, Slovenia, 1000
Slovenia Maribor, Slovenia, 2000